Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Mohanram G-Score: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score?

Sichuan Kelun-Biotech Biopharmaceutical Co does not have enough data to calculate Mohanram G-Score.

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score Related Terms


Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
N/A N/A N/A N/A N/A

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

HKSE:06990 vs VRTX, REGN, RVMD: Mohanram G-Score Comparison

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Mohanram G-Score falls into.


HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Mohanram G-Score: N/A
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value